Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rescigno Pasquale, Taha Tarek, Fita Maria J, Matthews Diana, Fujita Kazutoshi, Lolli Cristian, DI Costanzo Fabrizio, Juárez Alvaro, Ürün Yüksel, Yazgan Sati C, Li Haoran, Facchini Gaetano, Quiroga María N, Sammarco Enrico, Bögemann Martin, Santini Daniele, Baranseh Jalal, Roviello Giandomenico, Kopp Ray M, Fiala Ondřej, Büttner Thomas, Carrozza Francesco, Ansari Jawaher, Tural Deniz, Conteduca Vincenza, Molina-Cerrillo Javier, Alonso-Gordoa Teresa, Bourlon Maria T, Palacios Georgia A, Paolieri Federico, Zgura Anca, DI Rocco Roberta, Lacerenza Leonardo G, Matrana Marc R, Martignetti Angelo, Massari Francesco, Soares Andrey, Monteiro Fernando S, Bastos Diogo A, Gaughan Luke, Wenzel Mike, Mandel Philipp, Banna Giuseppe L, Santoni Matteo
Аннотация
METHODS: A retrospective analysis was conducted on 247 mHSPC patients treated with DARO+DOCE+ADT or ABI+DOCE+ADT across 37 institutions in 14 countries. Key outcomes included progression-free survival (PFS), overall survival (OS), PSA kinetics, and safety. A propensity score was estimated based on key clinical variables and included as a covariate in Cox regression models to adjust for baseline imbalances between treatment groups.
RESULTS: Data from 247 patients receiving triplet therapy were analyzed. The median OS for the entire cohort was not reached (NR). The median PFS was 24.8 months (95% CI: 18.7-33.6), with NR for DARO+DOCE+ADT and 21.5 months (95% CI: 13.1-25.2) for ABI+DOCE+ADT (P=0.007). In patients with visceral metastases, DARO+DOCE+ADT demonstrated superior outcomes, achieving higher OS rates at 6 months (97% vs. 83%, P=0.002) and 12 months (92% vs. 74%, P<0.001) compared to ABI+DOCE+ADT. The safety profiles of both regimens were comparable, although grade 3-4 fatigue was more frequently observed in the ABI+DOCE+ADT group. After adjusting for baseline imbalances through propensity score inclusion in multivariate models, the differences in OS (P=0.103) and PFS (P=0.135) between treatment groups did not reach statistical significance, although a numerical trend favoring DARO+DOCE+ADT was observed.
CONCLUSIONS: Both regimens demonstrate efficacy, with DARO+DOCE+ADT offering superior outcomes in high-volume disease, especially visceral metastases. Nonetheless, the limited sample size and potential biases highlight the need for further follow-up and biomarker-driven studies in larger cohorts to refine treatment strategies.